Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Exin Therapeutics

Request full access

AI-driven genetic therapies targeting neural circuit imbalances

San Francisco, United StatesFounded 2025Biotech & Life Sciences

About Exin Therapeutics

Exin Therapeutics is a biotechnology company founded in 2024 by a team of three Oxford-educated neuroscientists: Gabriel Ocana Santero, Ivan Lazarte, and Marko Tvrdic. The company, headquartered in San Francisco, operates as a participant in the Y Combinator Winter 2025 batch. The founding team combines extensive experience in neuroscience, gene therapy, biochemistry, and physics. Ivan Lazarte's personal motivation stems from his brother's experience with Autism Spectrum Disorder (ASD), driving the company's mission to improve the quality of life for patients with neurological conditions.

The firm is developing a platform for creating precision genetic therapies aimed at neurological and neuropsychiatric disorders by addressing them from a circuit-level perspective. Rather than focusing on correcting missing genes, Exin's approach involves supplementing existing genes to modify neural activity and correct imbalances between excitatory and inhibitory signals in brain circuits. This method is designed to be independent of a patient's specific genetic background. The company's initial focus is on conditions such as epilepsies associated with autism, Parkinson's disease, and debilitating symptoms of ASD.

A core component of Exin's strategy is its multimodal AI drug discovery platform. This platform utilizes machine learning to analyze high-density, in-house generated data from high-throughput mouse studies, including neural activity, behavior, and transcriptomics. The AI models identify disease drivers and predict the therapeutic potential of drug candidates, streamlining the preclinical R&D process and prioritizing the most promising assets for testing. This AI-guided approach aims to accelerate the traditionally slow process of developing drugs for brain disorders. The company has raised $500K in a seed funding round and is backed by investors including Y Combinator, 468 Capital, Multimodal Ventures, Tekedia Capital, and Theory Forge Ventures.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
1
Dealroom signal
70.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Neurology, Genetics and genomics, Precision Medicine, Gene Therapy, Brain Computer Interfaces, AI Drug Discovery, YC W25, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Mar 2025 $125K $500K Y Combinator —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Exin Therapeutics website traffic

Latest recorded traffic for Exin Therapeutics is 1K monthly website visits, up 0% over the last three months. Exin Therapeutics's team grew 133.3% over the past year.

Latest monthly visits1K 3-month web change0% 1-year team growth+133.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Exin Therapeutics in the San Francisco ecosystem

Live from Dealroom

The Exin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States50%
🇵🇭 Philippines33.3%
🇨🇭 Switzerland16.7%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Exin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Exin Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.